What Is Genitourinary Cancer? Types, Symptoms, and Treatment

Genitourinary cancer is an umbrella term for any cancer that forms in the urinary system or male reproductive organs. That includes the prostate, bladder, kidneys, testicles, penis, and the ureters that connect the kidneys to the bladder. Collectively these cancers represent a major share of all malignancies worldwide, and their incidence has been climbing for decades in most categories. The biology, typical patient profile, and treatment options vary enormously from one site to another, so understanding the landscape means looking at each cancer on its own terms.

Prostate Cancer

Prostate cancer is the most commonly diagnosed genitourinary malignancy and one of the most common cancers in men overall. Globally, its age-adjusted incidence has been rising since at least 1990, though mortality rates have actually fallen over the same period as screening and treatment have improved.¹ Countries with higher socioeconomic development tend to report higher incidence, partly because PSA screening catches more cases and partly because lifestyle risk factors like diet and obesity play a role.

Genetics matter here more than many people realize. Both common genetic variants spread across the population and rarer inherited mutations that cluster in families contribute to prostate cancer risk, together accounting for over a third of the familial risk.² The genetic picture also differs by race: tumors in Black men tend to carry different molecular alterations than those in White or Asian men, including more chromosome 8q gains, which is an unfavorable prognostic sign.³ These molecular differences are one reason researchers are pushing for screening and treatment strategies that account for ancestry, not just age.

Early-stage prostate cancer usually produces no symptoms at all, which is why screening with a blood test measuring prostate-specific antigen (PSA) remains important. When symptoms do appear, they tend to involve difficulty urinating, a weak stream, blood in the urine, or pelvic discomfort. A rising PSA level triggers further workup, often including MRI. A large randomized study found that using MRI to guide targeted biopsies, rather than performing systematic needle biopsies alone, reduced the detection of clinically insignificant low-grade cancers while still catching the aggressive ones.⁴ In practice that means fewer men undergoing unnecessary treatment for cancers that would never have harmed them.

Treatment depends heavily on how aggressive the cancer appears. For low-risk disease, active surveillance is a well-established approach: doctors monitor with regular PSA tests and periodic biopsies, stepping in only if the cancer shows signs of progressing. Early outcome data showed that the vast majority of men on surveillance remained safely observed for years, with none developing metastatic disease and none dying of prostate cancer during the follow-up period.⁵ For higher-risk prostate cancer, surgery (radical prostatectomy), radiation therapy, hormone therapy, and increasingly combinations of these are standard. High-dose-rate brachytherapy, a form of internal radiation, combined with external beam radiation produces higher cancer control rates than external radiation alone and is recommended for eligible intermediate- and high-risk patients.⁶

Bladder Cancer

Bladder cancer is the second most common genitourinary malignancy. Unlike most of the other cancers in this group, its age-adjusted incidence has actually been declining globally, while the absolute number of cases has still more than doubled since 1990 because populations are growing and aging.¹ It is far more common in men than women, with men diagnosed at roughly four times the rate.

Smoking is the dominant risk factor, responsible for roughly half of all bladder cancer cases.⁷ A large cohort study found that current smokers faced about four times the risk of developing bladder cancer compared with people who had never smoked, and even former smokers carried about twice the risk.⁸ Occupational exposure to certain industrial chemicals, particularly aromatic amines used in dye manufacturing and rubber processing, is the other major contributor. Genetic susceptibility is increasingly recognized, though its role is less well defined than for prostate cancer.

The hallmark symptom is blood in the urine. Most bladder cancers are diagnosed after a patient notices visible blood and seeks evaluation.⁹ Other symptoms can include painful or frequent urination and lower back pain, though these are easily mistaken for a urinary tract infection, which sometimes delays diagnosis. Confirmation comes from cystoscopy, where a camera is passed through the urethra into the bladder, followed by transurethral resection of any visible tumor. That resection also serves as the first stage of treatment.

About three-quarters of newly diagnosed bladder cancers are non-muscle-invasive, meaning the tumor has not grown into the muscular wall of the bladder. For these, the standard approach after initial resection is immunotherapy instilled directly into the bladder using BCG, a weakened form of the tuberculosis bacterium that provokes an immune attack on residual cancer cells. BCG reduces both recurrence and the chance of progression to more invasive disease.¹⁰ When non-muscle-invasive cancer recurs after BCG, decisions get complicated. Data from a large analysis found that among patients who needed additional treatment within the first year after BCG, survival outcomes were similar whether they received more bladder-directed therapy or had the bladder surgically removed (radical cystectomy).¹¹ That finding has given patients and doctors more room to consider bladder-sparing options.

Muscle-invasive bladder cancer, where the tumor has grown deeper, is a different situation. Radical cystectomy with urinary diversion is the most common treatment, often preceded by chemotherapy. Newer systemic options including immune checkpoint inhibitors and antibody-drug conjugates have transformed care for advanced disease.

Kidney Cancer

Kidney cancer, primarily renal cell carcinoma, accounts for roughly 3% of adult cancers but is a significant cause of cancer death.¹² Its incidence has been rising steadily since 1990, partly because widespread use of abdominal imaging for unrelated reasons catches small tumors that would previously have gone unnoticed.¹³ Known risk factors include smoking, obesity, and high blood pressure.

Kidney cancer is notoriously stealthy. It can grow to a substantial size before causing any symptoms, and the classic triad of flank pain, blood in the urine, and a palpable mass actually shows up in only a small fraction of patients. Many kidney cancers are found incidentally during a CT scan or ultrasound done for something else entirely. This trend toward earlier, incidental detection has somewhat improved survival statistics, though kidney cancer still has the unwelcome distinction of being resistant to conventional chemotherapy and radiation.

For localized disease, surgery remains the cornerstone, ranging from partial removal of the kidney (nephron-sparing surgery) for smaller tumors to complete removal for larger or more aggressive ones. When the cancer has spread, the treatment landscape has been reshaped by targeted drugs that block the blood supply tumors need to grow, along with immune checkpoint inhibitors. Combinations of these two drug classes have produced higher response rates than either approach alone.¹⁴ Specific combinations pairing a checkpoint inhibitor with a targeted drug have now become standard first-line treatment for metastatic kidney cancer.¹⁵

Testicular Cancer

Testicular cancer stands apart from the others because it typically strikes young men. It is the most common malignancy in men between about 14 and 44 years of age, and its incidence has been climbing in Western countries over the past two decades.¹⁶ The most established risk factor is cryptorchidism, where one or both testicles fail to descend into the scrotum during development. A family history of testicular cancer also raises risk modestly.

The usual first sign is a painless lump or swelling in one testicle, sometimes accompanied by a dull ache in the groin or lower abdomen. Diagnosis involves ultrasound imaging and blood tests for serum tumor markers, including alpha-fetoprotein, human chorionic gonadotropin, and lactate dehydrogenase.¹⁷ Prognostic features like tumor size, whether the cancer has invaded blood vessels, and the specific type of tumor cells all guide treatment decisions.¹⁸

The good news is that testicular cancer is one of the most curable solid tumors. For early-stage tumors without spread, surgical removal of the affected testicle (orchiectomy) alone produces cure rates around 80 to 85%. When precancerous changes are caught even earlier, organ-sparing approaches like focused radiation can push cure rates to about 98%.¹⁹ Even advanced testicular cancer that has spread to lymph nodes or beyond responds well to platinum-based chemotherapy, giving most men an excellent long-term prognosis.

Penile Cancer and Upper Tract Urothelial Cancer

Penile cancer is rare, particularly in developed countries, but its incidence has been increasing in some regions. It is primarily a squamous cell cancer, and roughly 40% of cases are linked to human papillomavirus (HPV) infection.²⁰ Other risk factors include the absence of childhood circumcision, chronic inflammation, poor hygiene, smoking, and immunosuppression.²¹ HPV vaccination, already recommended for prevention of cervical and other cancers, also has the potential to reduce penile cancer rates over time. Treatment ranges from topical therapies and minor surgery for superficial tumors to more extensive surgical resection for advanced disease. Immune checkpoint inhibitors have shown some promise for HPV-associated penile cancers specifically.²²

Upper tract urothelial carcinoma forms in the lining of the renal pelvis or ureters, the tubes that carry urine from the kidneys to the bladder. It is a distinct entity from bladder cancer even though both arise from the same cell type. Upper tract tumors tend to behave more aggressively and affect older patients.²³ Surgical removal of the kidney, ureter, and a cuff of the bladder remains the standard treatment, though kidney-sparing endoscopic approaches are an option for selected patients, particularly those with a single functioning kidney or significant health problems that make major surgery risky.²⁴ Lifelong surveillance after treatment is necessary because these tumors have a high rate of recurrence, including the development of new cancers in the bladder.

How Immunotherapy and Targeted Drugs Are Reshaping Treatment

Across genitourinary cancers, the biggest treatment revolution over the past decade has been the rise of immune checkpoint inhibitors. These drugs work by releasing the brakes that cancer cells place on the immune system, allowing the body’s own defenses to attack the tumor. They have secured regulatory approval for kidney cancer and bladder cancer and are being tested across nearly every other genitourinary tumor type.²⁵ The response to checkpoint inhibitors varies widely: kidney cancer and some bladder cancers respond relatively well, while prostate cancer and testicular cancer have shown more limited sensitivity so far.

Antibody-drug conjugates represent another leap forward, particularly for urothelial cancers of the bladder and upper tract. These engineered drugs attach a potent chemotherapy molecule to an antibody that recognizes a protein found mainly on tumor cells. The antibody delivers its toxic cargo directly to the cancer, causing less damage to healthy tissue than traditional chemotherapy would.²⁶ Two such drugs, enfortumab vedotin and sacituzumab govitecan, have received regulatory approval for advanced urothelial cancer. Enfortumab vedotin combined with a checkpoint inhibitor has become a preferred regimen for patients whose cancer has progressed after initial treatment, and trials are now exploring whether this combination could replace chemotherapy as a first-line option.

An area of growing interest is the body’s own microbiome and its role in treatment response. Early data suggest that the bacteria living in and around the bladder may influence how well immunotherapy works, with a healthy microbial community appearing to improve outcomes.²⁷ This research is still in its early stages, but it has prompted investigators to study whether manipulating the microbiome through diet, probiotics, or fecal transplant could someday augment cancer treatment.

Disparities in Care and Outcomes

Not everyone with genitourinary cancer receives the same quality of care, and the consequences are measurable. Research on bladder cancer in California found that Black patients and patients with Medicaid insurance experienced worse survival than White patients and those with private insurance. The gap was linked to concrete differences in the care pathway: Black patients were less likely to receive timely imaging, cystoscopy referrals, and standard-of-care surgery. When they did have surgery, it was more often at lower-volume hospitals with less experienced surgeons.²⁸ Similar patterns have been documented in prostate and kidney cancer. Addressing these disparities requires systemic changes in access, referral networks, and insurance coverage, not just awareness.

Fertility Preservation

Because testicular cancer hits young men squarely during their reproductive years, fertility is often one of the first concerns after diagnosis. Both surgery and chemotherapy can impair sperm production, sometimes permanently. The American Society of Clinical Oncology recommends discussing fertility risks and offering preservation options as early as possible.²⁹ Sperm banking before treatment, ideally even before orchiectomy, maximizes the chance of biological fatherhood later.³⁰ Despite this, fertility preservation remains significantly underutilized. Many patients report never having had the conversation with their doctor before treatment began.³¹

Bladder and prostate cancer treatments can also affect sexual and urinary function in ways that erode quality of life. After radical prostatectomy, urinary incontinence and erectile dysfunction are common. A study of German cancer survivors found that a substantial share of those affected reported moderate-to-severe problems with worse mental health scores and reduced social functioning.³² Among U.S. prostate cancer survivors, roughly a third developed a urinary adverse event after primary treatment, with incontinence and strictures being the most common.³³ Treatments for these side effects exist, from pelvic floor rehabilitation and medications to surgical implants, but the evidence consistently shows that too few survivors access them.

Artificial Intelligence in Diagnosis

One of the more practical near-term developments in genitourinary cancer care is the use of artificial intelligence to read prostate MRI scans. A large international study compared an AI system to 62 radiologists and found the AI matched or outperformed the doctors: it detected about 7% more clinically significant cancers at the same rate of false alarms, or alternatively cut false-positive results by about half while catching the same number of dangerous cancers.³⁴ A meta-analysis of machine learning-based MRI interpretation across twelve studies similarly reported high accuracy, with pooled sensitivity above 90% for distinguishing cancerous from non-cancerous prostates.³⁵

The practical upshot is not that AI will replace radiologists, but that it can act as a second reader, flagging suspicious areas that a human might miss and reducing the variability that comes from different radiologists interpreting the same scan differently.³⁶ Meanwhile, liquid biopsy approaches are being explored for monitoring advanced prostate cancer by detecting tumor-related proteins on circulating cancer cells in a blood sample, potentially offering a less invasive alternative to repeated imaging.³⁷ Neither technology has fully replaced conventional approaches, but both are moving from research settings into clinical practice faster than most observers expected.